Sandoz H2 Launch Ramp-Up Begins With A US First
Novartis Subsidiary Launches High Dose Intravenous Iron, Ferumoxytol Injection
Executive Summary
Sandoz has kicked off what promises to be a busy second half of 2021 in terms of launches for the Novartis subsidiary, introducing the first US generic of the Feraheme feumoxytol injectable treatment for iron deficiency anemia.